179 related articles for article (PubMed ID: 25951987)
1. Mechanisms involved in quinolone resistance in Mycoplasma mycoides subsp. capri.
Antunes NT; Assunção P; Poveda JB; Tavío MM
Vet J; 2015 Jun; 204(3):327-32. PubMed ID: 25951987
[TBL] [Abstract][Full Text] [Related]
2. Resistance mechanisms against quinolones in Mycoplasma capricolum subsp. capricolum.
Tatay-Dualde J; Prats-van der Ham M; de la Fe C; Paterna A; Sánchez A; Corrales JC; Contreras A; Gómez-Martin Á
Vet J; 2017 May; 223():1-4. PubMed ID: 28671064
[TBL] [Abstract][Full Text] [Related]
3. Characterization of mutations in DNA gyrase and topoisomerase IV Involved in quinolone resistance of Mycoplasma gallisepticum mutants obtained in vitro.
Reinhardt AK; Bébéar CM; Kobisch M; Kempf I; Gautier-Bouchardon AV
Antimicrob Agents Chemother; 2002 Feb; 46(2):590-3. PubMed ID: 11796386
[TBL] [Abstract][Full Text] [Related]
4. In vitro assessment of the antimicrobial susceptibility of caprine isolates of Mycoplasma mycoides subsp. capri.
Paterna A; Tatay-Dualde J; Amores J; Prats-van der Ham M; Sánchez A; de la Fe C; Contreras A; Corrales JC; Gómez-Martín Á
Vet J; 2016 Aug; 214():96-101. PubMed ID: 27387734
[TBL] [Abstract][Full Text] [Related]
5. Fluoroquinolone resistance in Mycoplasma gallisepticum: DNA gyrase as primary target of enrofloxacin and impact of mutations in topoisomerases on resistance level.
Reinhardt AK; Kempf I; Kobisch M; Gautier-Bouchardon AV
J Antimicrob Chemother; 2002 Oct; 50(4):589-92. PubMed ID: 12356806
[TBL] [Abstract][Full Text] [Related]
6. Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.
Rafii F; Park M; Novak JS
Antimicrob Agents Chemother; 2005 Feb; 49(2):488-92. PubMed ID: 15673722
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of plasmid-mediated quinolone resistance and mutations in the gyrase and topoisomerase IV genes in Salmonella isolated from 12 tertiary-care hospitals in Korea.
Jeong HS; Kim JA; Shin JH; Chang CL; Jeong J; Cho JH; Kim MN; Kim S; Kim YR; Lee CH; Lee K; Lee MA; Lee WG; Shin JH; Lee JN
Microb Drug Resist; 2011 Dec; 17(4):551-7. PubMed ID: 21830947
[TBL] [Abstract][Full Text] [Related]
8. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
Strahilevitz J; Hooper DC
Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
[TBL] [Abstract][Full Text] [Related]
9. Single-nucleotide polymorphism mutation spectra and resistance to quinolones in Salmonella enterica serovar Enteritidis with a mutator phenotype.
Levy DD; Sharma B; Cebula TA
Antimicrob Agents Chemother; 2004 Jul; 48(7):2355-63. PubMed ID: 15215081
[TBL] [Abstract][Full Text] [Related]
10. Contribution of topoisomerase IV mutation to quinolone resistance in Mycoplasma genitalium.
Yamaguchi Y; Takei M; Kishii R; Yasuda M; Deguchi T
Antimicrob Agents Chemother; 2013 Apr; 57(4):1772-6. PubMed ID: 23357772
[TBL] [Abstract][Full Text] [Related]
11. Resistance to fluoroquinolones by the combination of target site mutations and enhanced expression of genes for efflux pumps in Shigella flexneri and Shigella sonnei strains isolated in Korea.
Kim JY; Kim SH; Jeon SM; Park MS; Rhie HG; Lee BK
Clin Microbiol Infect; 2008 Aug; 14(8):760-5. PubMed ID: 18727800
[TBL] [Abstract][Full Text] [Related]
12. Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus.
Oizumi N; Kawabata S; Hirao M; Watanabe K; Okuno S; Fujiwara T; Kikuchi M
J Infect Chemother; 2001 Sep; 7(3):191-4. PubMed ID: 11810583
[TBL] [Abstract][Full Text] [Related]
13. Sitafloxacin: antimicrobial activity against ciprofloxacin-selected laboratory mutants of Mycoplasma genitalium and inhibitory activity against its DNA gyrase and topoisomerase IV.
Deguchi T; Kikuchi M; Yasuda M; Ito S
J Infect Chemother; 2015 Jan; 21(1):74-5. PubMed ID: 25245990
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of mutations within the quinolone resistance-determining region of gyrA, gyrB, parC, and parE and association with antibiotic resistance in quinolone-resistant Salmonella enterica.
Eaves DJ; Randall L; Gray DT; Buckley A; Woodward MJ; White AP; Piddock LJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):4012-5. PubMed ID: 15388468
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and characterisation of plasmid-mediated quinolone resistance and mutations in the gyrase and topoisomerase IV genes among Shigella isolates from Henan, China, between 2001 and 2008.
Yang H; Duan G; Zhu J; Zhang W; Xi Y; Fan Q
Int J Antimicrob Agents; 2013 Aug; 42(2):173-7. PubMed ID: 23796894
[TBL] [Abstract][Full Text] [Related]
16. In vitro development of resistance to DX-619 and other quinolones in enterococci.
Wickman PA; Black JA; Smith Moland E; Thomson KS; Hanson ND
J Antimicrob Chemother; 2006 Dec; 58(6):1268-73. PubMed ID: 17062613
[TBL] [Abstract][Full Text] [Related]
17. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
Okumura R; Hirata T; Onodera Y; Hoshino K; Otani T; Yamamoto T
J Antimicrob Chemother; 2008 Jul; 62(1):98-104. PubMed ID: 18390884
[TBL] [Abstract][Full Text] [Related]
18. Amino acid substitutions of quinolone resistance determining regions in GyrA and ParC associated with quinolone resistance in Acinetobacter baumannii and Acinetobacter genomic species 13TU.
Liu YH; Kuo SC; Lee YT; Chang IC; Yang SP; Chen TL; Fung CP
J Microbiol Immunol Infect; 2012 Apr; 45(2):108-12. PubMed ID: 22153765
[TBL] [Abstract][Full Text] [Related]
19. Impact of mutations in DNA gyrase genes on quinolone resistance in Campylobacter jejuni.
Changkwanyeun R; Yamaguchi T; Kongsoi S; Changkaew K; Yokoyama K; Kim H; Suthienkul O; Usui M; Tamura Y; Nakajima C; Suzuki Y
Drug Test Anal; 2016 Oct; 8(10):1071-1076. PubMed ID: 26857529
[TBL] [Abstract][Full Text] [Related]
20. Discrepancy between minimal inhibitory concentration to enrofloxacin and mutations present in the quinolone-resistance determining regions of Mycoplasma gallisepticum field strains.
Lysnyansky I; Gerchman I; Levisohn S; Mikula I; Feberwee A; Ferguson NM; Noormohammadi AH; Spergser J; Windsor HM
Vet Microbiol; 2012 Nov; 160(1-2):222-6. PubMed ID: 22655973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
